NKF(SH:603707) Mei Ri Jing Ji Xin Wen·2025-08-21 08:25Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received FDA approval for its Nicardipine Hydrochloride Injection, which is expected to positively impact its business performance [1] Group 1: Product Approval - The FDA has issued an approval letter for Nicardipine Hydrochloride Injection, 25mg/10mL (2.5mg/mL) under ANDA number 216819 [1] - The approved drug is indicated for the short-term treatment of hypertension when oral therapy is not feasible [1] Group 2: Investment and Market Impact - The company has invested approximately RMB 18.3543 million in the research and development of this project [1] - The newly approved product is set to be launched in the U.S. market soon, which is anticipated to have a positive effect on the company's operating performance [1]